< Back to Article
Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China
Fig 3
Cost-effectiveness acceptability curves of sacituzumab tirumotecan versus chemotherapy.
WTP, willingness-to-pay; QALY, quality-adjusted life-year.
doi: https://doi.org/10.1371/journal.pone.0343330.g003